Results 161 to 170 of about 8,864 (209)

Hepatopulmonary Shunt Reduction With 177Lu-DOTATATE Therapy

Clinical Nuclear Medicine, 2016
A 72-year-old man was diagnosed with well-differentiated neuroendocrine tumor of unknown primary with liver metastasis. All liver lesions were detectable only on Ga-DOTATATE PET/CT and were negative on F-FDG PET/CT. Intrahepatic Y radioembolization therapy was planned, but the hepatopulmonary shunt fraction was found to be 31.6%.
Emine, Acar, Gamze, Çapa Kaya, Hatice, Durak   +2 more
openaire   +2 more sources

Prognostic stratification for patients with neuroendocrine tumours receiving 177Lu-Dotatate

Endocrine-Related Cancer, 2022
177 Lu-Dotatate is increasingly used in patients with advanced neuroendocrine tumour (NET). However, few prognostic markers are available to stratify progression-free survival (PFS) of patients who received 177 Lu-Dotatate.
Luohai Chen, Gopinath Gnanasegaran, Dalvinder Mandair, Christos Toumpanakis, Martyn Caplin, Shaunak Navalkissoor   +5 more
openaire   +2 more sources

Liver Steatosis Secondary to PRRT With 177Lu-DOTATATE

Clinical Nuclear Medicine, 2020
Abstract PRRT (peptide receptor radionuclide therapy) with 177Lu-DOTATATE for neuroendocrine tumor has some well-known adverse effects, concerning specially the bone marrow and kidneys. Hepatotoxicity has been rarely reported, and there are no data regarding hepatic steatosis secondary to PRRT. We reviewed upper abdomen CT and MRI and applied
Beatriz Matheos, de Lima, Juliana Ribeiro, de Carvalho, Priscilla Romano, Gaspar, Priscilla Brunelli, Pujatti, Rinaldo, Gonçalves   +4 more
openaire   +2 more sources

Thymoma Treated With 177Lu DOTATATE Induction and Maintenance PRRT

Clinical Nuclear Medicine, 2015
A 47-year-old man presented with a recurrent thymoma World Health Organization type A of the anterior chest wall with pleural metastases after failing chemotherapy. The tumor was positive on In-octreotide, and he was referred for peptide receptor radionuclide therapy (PRRT) with Lu DOTATATE.
William, Makis, Karey, McCann, Alexander J B, McEwan   +2 more
openaire   +2 more sources

Radiation Safety Observations Associated with 177Lu Dotatate Patients

Health Physics, 2019
Abstract Lutetium-177 dotatate, marketed under the name Lutathera®, is proving to be a valuable tool for physicians treating patients with neuroendocrine somatostatin-receptive tumors. Treatment consists of four cycles of 7.4 GBq of 177Lu dotatate infused intravenously over 30 to 40 minutes.
Kevin L, Nelson, Michael A, Sheetz
openaire   +2 more sources

Rhabdoid Papillary Meningioma Treated With 177Lu DOTATATE PRRT

Clinical Nuclear Medicine, 2015
An 18-year-old girl presented with a 3-year history of a recurrent skull base mass confirmed to be a rhabdoid papillary meningioma. The tumor was octreotide avid and metastatic to the lungs, thoracic lymph nodes, and bones, and she was referred for PRRT (peptide receptor radionuclide therapy) with 177Lu DOTATATE.
William, Makis, Karey, McCann, Alexander J B, McEwan   +2 more
openaire   +2 more sources

Peptide Receptor Radionuclide Therapy by 177Lu-DOTATATE of a Secreting Cervical Paraganglioma

Clinical Nuclear Medicine, 2021
Abstract A 59-year-old man with a parapharyngeal paraganglioma incidentally discovered on a cervical swelling was referred to our nuclear medicine department for a morpho-metabolic assessment. An 18F-FDG PET/CT was initially performed and found an intense hypermetabolism of the lesion and a hypermetabolism of the periadrenal brown fat evoking
Agathe, Deville, Iuliia, Pinigina, Laure, Al Mansour, Juliette, Abeillon, Jeremie, Tordo   +4 more
openaire   +2 more sources

Salvage 177Lu-dotatate therapy in patients with progressive metastatic neuroendocrine tumors.

Journal of Clinical Oncology, 2022
e16212 Background: 177Lu-dotatate (LuPRRT) is effective in selected patients with metastatic neuroendocrine tumours (NETs). Most of these patients will subsequently have progressive disease with limited treatment options available. We analyzed the outcomes and toxicities of salvage LuPRRT in this study.
Hoe, Hui Jing, Wyld, David
openaire   +3 more sources

[Clinical Practice of 177Lu-DOTATATE in the Treatment of Neuroendocrine Tumors].

Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2023
Most of the neuroendocrine tumors(NETs) overexpress the somatostatin receptor(SSTR),which provides a reliable target for SSTR-targeted peptide receptor radionuclide therapy(PRRT).Compared with drug therapy,PRRT has high objective response rate and significantly prolongs patients' survival.Moreover,the patients have good tolerance to this therapy ...
Li-Meng, He, Ying, Deng, An-Bo, Wang, Nan, Liu, Yue, Chen, Xue-Xian, Yan, Wei, Zhang   +6 more
openaire   +1 more source

Radiation exposure after 177Lu-DOTATATE and 177Lu-PSMA-617 therapy

Annals of Nuclear Medicine, 2018
As radionuclide therapy is gaining importance in palliative treatment of patients suffering from neuroendocrine tumour (NET) as well as castration resistant prostate cancer (CRPC), the radiation protection of patients, staff, family members and the general public is of increasing interest.
Christian, Mair, Boris, Warwitz, Katharina, Fink, Lorenza, Scarpa, Bernhard, Nilica, Johanna, Maffey-Steffan, Sabine, Buxbaum, Irene J, Virgolini   +7 more
openaire   +2 more sources